US FDA OK's revised labelling for Merck's Isentress
This article was originally published in Scrip
Executive Summary
The US FDA approved revised labelling for Merck's HIV drug Isentress (raltegravir), permitting the Whitehouse Station, New Jersey pharma giant to include data that showed a combination regimen containing the drug demonstrated long-term viral suppression, a greater immunologic response and a proven safety and tolerability profile at 156 weeks.